Special Report

Standards of diagnostic colonoscopy for early-stage neoplasia: Recommendations by an Asian private group

Yasushi Sano,1 Han-Mo Chiu,9 Xiao-bo Li,10 Supakij Khomvilai,13 Pises Pisesponsa,14 Jonard Tan Co,15 Takuji Kawamura,9 Nozomu Kobayashi,4 Shinji Tanaka,5 David G. Hewett,16 Yoji Takeuchi,6 Kenichiro Imai,7 Takahiro Utsumi,3 Akira Teramoto,1 Daizen Hirata,1 Mineo Iwatate,1 Rajvinder Singh,17 Siew C. Ng,11 Shiaw-Hooi Ho,18 Philip Chiu12 and Hisao Tajiri8

1Gastrointestinal Center and Institute of Minimally invasive Endoscopic Care (IMEC), Sano Hospital, Hyogo,
2Department of Gastroenterology, Kyoto Second Red Cross Hospital, 3Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine, Kyoto, 4Department of Gastroenterology, Tochigi Cancer Center, Tochigi, 5Department of Endoscopy, Hiroshima University Hospital, Hiroshima, 6Department of Gastrointestinal Oncology, Osaka International Cancer Institute, Osaka, 7Division of Endoscopy, Shizuoka Cancer Center, Shizuoka, 8Department of Innovative Interventional Endoscopy Research, The Jikei University School of Medicine, Tokyo, Japan, 9Department of Internal Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan, 10Division of Gastroenterology and Hepatology, Key Laboratory of Gastroenterology and Hepatology, Ministry of Health, Renji Hospital, School of Medicine, Shanghai Institute of Digestive Disease, Shanghai Jiao Tong University, Shanghai, 11Departments of Medicine and Therapeutics, 12and Surgery, Institute of Digestive Disease, State Key Laboratory of Digestive Diseases, LKS Institute of Health Science, The Chinese University of Hong Kong, Hong Kong, China, 13Surgical Endoscopy, Colorectal Surgery, Department of Surgery, Chulalongkorn University, 14Digestive Disease Center, Bumrungrad International Hospital, Bangkok, Thailand, 15St. Luke’s Medical Centre - Global City, Taguig City, Metro Manila, Philippines, 16Faculty of Medicine, University of Queensland, Brisbane, 17Gastroenterology Unit, Division of Medicine, Lyell McEwin Hospital, School of Medicine, The University of Adelaide, Adelaide, Australia and 18Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia

Background and Aim: In recent years, the incidence of colorectal cancer has been increasing, and it is now becoming the major cause of cancer death in Asian countries. The aim of the present study was to develop Asian expert-based consensus to standardize the preparation, detection and characterization for the diagnosis of early-stage colorectal neoplasia.

Methods: A professional group was formed by 36 experts of the Asian Novel Bio-Imaging and Intervention Group (ANBiIG) members. Representatives from 12 Asia-Pacific countries participated in the meeting. The group organized three consensus meetings focusing on diagnostic endoscopy for gastrointestinal neoplasia. The Delphi method was used to develop the consensus statements.

Results: Through the three consensus meetings with debating, reviewing the literature and regional data, a consensus was reached at third meeting in 2016. The consensus was reached on a total of 10 statements. Summary of statements is as follows: (i) Adequate bowel preparation for high-quality colonoscopy; (ii) Antispasmodic agents for lesion detection; (iii) Image-enhanced endoscopy (IEE) for polyp detection; (iv) Adenoma detection rate for quality indicators; (v) Good documentation of colonoscopy findings; (vi) Complication rates; (vii) Cecal intubation rate; (viii) Cap-assisted colonoscopy (CAC) for polyp detection; (ix) Macroscopic classification using indigocarmine spray for characterization of colorectal lesions; and (x) IEE and/or magnifying endoscopy for prediction of histology.

Conclusion: This consensus provides guidance for carrying out endoscopic diagnosis and characterization for early-stage colorectal neoplasia based on the evidence. This will enhance the quality of endoscopic diagnosis and improve detection of early-stage colorectal neoplasia.

Corresponding: Yasushi Sano, Gastrointestinal Center and Institute of Minimally Invasive Endoscopic Care (IMEC), Sano Hospital, 2-5-1 Shimizugaoka, Tarumi-ku, Kobe, Hyogo 655-0031, Japan. Email: ys_endoscopy@hotmail.com
Received 23 October 2018; accepted 24 December 2018.

© 2018 The Authors. Digestive Endoscopy published by John Wiley & Sons Australia, Ltd on behalf of Japan Gastroenterological Endoscopy Society. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
INTRODUCTION

In recent years, the incidence of colorectal cancer (CRC) has been increasing, and it is now becoming the major cause of cancer death in Asian countries. Fecal immunochemical test (FIT) is widely used for CRC screening, and its effectiveness in reducing CRC incidence and mortality has been shown in Asia. Several studies have also recently indicated the effectiveness of screening colonoscopy for reducing CRC incidence and mortality. Although CRC screening colonoscopy is not adopted as a primary population-based screening tool, the number of colonoscopies for screening objectives after FIT is increasing in Asia.

When a patient undergoes colonoscopy, the most important task for colonoscopists is not to miss or overlook any colorectal neoplasia, especially early-stage CRC. Early-stage CRC is defined as cancer that is confined to the mucosa or submucosa and does not invade the muscularis propria. Intramucosal cancer is virtually never associated with lymph node metastasis and can be curatively resected by colonoscopy. Once the submucosal layer is invaded, lymph node metastasis occurs in 6–13% of cases. However, shallow submucosal invasion (SM1 or T1a), especially invasion with a vertical depth of <1000 μm from the lower border of the muscularis mucosae, can still be treated endoscopically, depending on its lateral size, endoscopic features, and histopathological features.

Colonoscopy plays a fundamental role in the prevention and management of CRC and is used for both diagnosis and treatment of early CRC and its precursor lesions. Improvements in colonoscopy preparation, documentation, new techniques of adenoma detection, and recent progress in endoscopic imaging methods are providing higher quality results and reducing the incidence and mortality of the disease.

Against this background, the Asian Novel Bio-Imaging and Intervention Group (ANBI2G), which is an academic interest group, was established as a non-governmental organization (NGO) in Hong Kong in February 2014 (http://www.anbig.org/). Consisting of world-class healthcare professionals (HCP) in Asia, its objectives are to: (i) promote training and education in early gastrointestinal (GI) cancer diagnosis and therapy in the Asia–Pacific region; (ii) develop strategies and action plans for the professional development of endoscopists in the Asia–Pacific region; and (iii) work with any society, association or person for the purpose of furthering the education efforts of the society.

Contrary to this trend, in Asian countries, there is no consensus on diagnostic colonoscopy to recognize and characterize early-stage colorectal neoplasia. Therefore, ANBI2G members have held meetings over the past 2 years to refine the consensus for diagnostic endoscopy in Asia. The aim of the present study was to develop Asian expert-based consensus to standardize the preparation, detection and characterization for diagnosis of early-stage colorectal neoplasia.

METHODS

A PROFESSIONAL GROUP was formed by 36 expert ANBI2G members in 2016. Representatives from 12 Asia–Pacific countries participated in the meeting; these included Australia, China, India, Indonesia, Japan, Malaysia, Myanmar, Philippines, Singapore, Korea, Taiwan, Thailand, and Vietnam. The group organized three consensus meetings focusing on diagnostic endoscopy for GI neoplasia.

First consensus meeting (22–24 January, 2016, ANA Crowne Plaza Hotel, Kobe, Japan)

The first face-to-face meeting focused on drafting the consensus statements on standards of diagnostic lower GI endoscopy according to the following areas:

1. Standard preparation for diagnostic endoscopy.
2. Endoscopic recognition of early GI neoplasia.
3. Endoscopic characterization of early GI neoplasia.

An initial draft of 10 statements was formulated, discussed and agreed by the panel of experts. Each member was assigned to search for evidence of the respective statement and then prepare for discussion and voting in the following consensus meetings.

The literature search for each statement was based on publications in English from various scientific databases including AMED, BIOSIS previews, EBM reviews, Embase, Ovid MEDLINE, Cochrane Trials and systematic reviews.

PICO method for establishment of statements

The Problem/Population; Intervention; Comparison and Outcome method (PICO) was used to identify the appropriate interventions and standards for diagnostic endoscopy focusing on detection and characterization of early GI neoplasia as a clinical outcome. All statements were established following the PICO worksheet (Fig. 1).
Delphi method for voting

The expert panel formulated statements in two separate rounds of voting and opinion collection (Fig. 2). After each round, facilitators provided summaries of expert opinions from the previous round for refinement. If consensus was not achieved, the process was continued through discussion to work towards building one. The voting was based on reviews of the literature on a Likert scale ranging from 1 to 5 (1 = accept completely, 2 = accept with some reservation,

PICO Worksheet and Search Strategy

Name___________________

1. Define your question using PICO by identifying the Problem, Intervention, Comparison Group and Outcomes.
Your question should be used to help establish your search strategy.

| Patient/Problem | Intervention | Comparison | Outcome |
|-----------------|-------------|------------|---------|

Write out the Statement:
______________________________________________________________________________
______________________________________________________________________________

2. Type of question/problem: Circle one:
Therapy/Prevention Diagnosis Etiology Prognosis

3. Type of study (Publication Type) to include in the search: Check all that apply:
- Meta-Analysis
- Systematic Review
- Randomized Controlled Trial
- Cohort Study
- Case Control Study
- Case series or Case Report
- Editorials, Letters, Opinions
- Animal Research
- In Vitro/Lab Research

4. List main topics and alternative terms from your PICO question that can be used for your search
List your inclusion criteria – gender, age, year of publication, language
List irrelevant terms that you may want to exclude in your search

5. List where you plan to search, i.e. EBM Reviews, Medline, AIDSLINE, CINAHL, PubMed

Figure 1 Problem/Population; Intervention; Comparison and Outcome (PICO) Worksheet and Search Strategy.

Figure 2 Delphi method.
3 = accept with major reservation, 4 = reject with reservation, 5 = reject completely). All voting was held at the end of the talks using a wireless polling system to ensure anonymity.

Consensus was achieved when >80% of members indicated that they accepted the statement completely or accepted it with some reservation. When consensus was not reached at the first vote, panel members discussed the statement again for further modification. This was followed by a second round of voting. If there was still failure to reach a consensus, the statement was rejected. Each statement was graded on the level of evidence and strength of recommendation (Tables 1 and 2).

Second consensus meeting (23–24 June 2016, Swissotel Nankai, Osaka, Japan)

After the search for evidence on 10 statements, a second face-to-face meeting was conducted in order to vote on and refine the statements. An appropriate time was allowed for each statement through discussion among members to allow for refinement. After the meeting, a period of 5 months was allowed for further collection of comments through a closed group internet platform.

Table 1: Quality of evidence summarized for each of the statements will be graded according to the classification below

| Level of Evidence | Description |
|-------------------|-------------|
| I                 | Evidence obtained from at least one randomized controlled trial |
| II-1              | Evidence obtained from well-designed control trials without randomization |
| II-2              | Evidence obtained from a well-designed cohort or case–control study |
| II-3              | Evidence obtained from comparison between time or places with or without intervention |
| III               | Opinion of respected authorities, based on clinical experience and expert committees |

Table 2: Classification of recommendations

| Grade of Recommendation | Description |
|-------------------------|-------------|
| A                       | There is good evidence to support the statement |
| B                       | There is fair evidence to support the statement |
| C                       | There is poor evidence to support the statement but recommendation made on other grounds |
| D                       | There is fair evidence to refute the statement |
| E                       | There is good evidence to refute the statement |

Third consensus meeting (6 November 2016, Sano Hospital, Kobe, Japan)

All of the experts in the panel joined the third consensus face-to-face meeting and accomplished the final version of the 10 statements after updating these statements based on the latest evidence. Then, we took an anonymous vote on all of the statements (Fig. 3).

RESULTS

Level of agreement for each consensus statement

Agreement on each statement was achieved when more than 80% of the members indicated that they accepted the statement completely or accepted it with some reservation in an anonymous vote using the Delphi method in Sano Hospital. Of the total 10 statements, all statements reached consensus after the first-round vote (accepted by 100%; Table 3). No statements were rejected or went to the second-round vote.

Consensus statements

Consensus was reached on a total of 10 statements as follows:

Statement 1: Adequate bowel preparation is essential for high-quality colonoscopy

Level of agreement: (i) accept completely 78%; (ii) accept with some reservation 18%; (iii) accept with major reservation 4%; (iv) reject with reservation 0%; (v) reject completely 0%.

Level of evidence: II-2.

Level of recommendation: B.

Clinical question: Is adequate bowel preparation essential to ensure high-quality colonoscopy?

High-quality colonoscopy reduces the risk of CRC by detecting and removing polyps that could potentially develop into cancers. The adenoma detection rate (ADR) is one of the quality indicators for colonoscopy. As bowel preparation quality affects the visualization of colonic mucosa and polyps, it has a direct impact on the ADR. A few studies have shown that the polyp detection rate in patients with adequate bowel preparation is higher than in patients with inadequate bowel preparation. Furthermore, one meta-analysis has shown that good bowel preparation is significantly associated with higher ADR. Two tandem colonoscopy studies confirmed...
that the number of missed polyps was increased in patients with poor bowel preparation.\textsuperscript{17,18}

**Statement 2: Use of antispasmodic agents during colonoscopy is useful for lesion detection**

Level of agreement: (i) accept completely 58%; (ii) accept with some reservation 34%; (iii) accept with major reservation 4%; (iv) reject with reservation 4%; (v) reject completely 0%.

Level of evidence: I.

Level of recommendation: C.

Clinical question: Are antispasmodic agents useful for colonoscopy?

Giving antispasmodic agents during screening and surveillance colonoscopy aims to minimize technical difficulties, reduce patient discomfort and reduce the likelihood of missing neoplastic lesions. Several randomized controlled trials (RCT) have reported technical problems related to the use of hyoscine butylbromide as an antispasmodic agent during colonoscopy.\textsuperscript{19–24} Some RCT have shown that cecal intubation time is shorter in patients given antispasmodic agents,\textsuperscript{19,21} whereas other RCT have concluded that antispasmodic agents are not beneficial for colonoscope insertion.\textsuperscript{20,22–24} In terms of patient discomfort, one RCT has indicated that antispasmodic agents are beneficial.\textsuperscript{21} Therefore, giving antispasmodic agents to minimize technical difficulties and patient discomfort is still controversial. Recently, several meta-analyses on the use of antispasmodic agents during colonoscopy for lesion detection have been published.\textsuperscript{25–28} None of them concluded that the use of antispasmodic agents improved the detection rate of either adenomas or polyps. However, one RCT showed that hyoscine butylbromide increased the number of polyps identified per patient.\textsuperscript{29} Furthermore, a large-scale retrospective study of data from the English Bowel Cancer Screening Programme showed that the routine use of hyoscine butylbromide was associated with a 30% higher rate of adenoma detection.\textsuperscript{30} Therefore, the use of antispasmodic agents during colonoscopy may be helpful for detection of lesions.

**Statement 3-1: Image-enhanced endoscopy (IEE) can improve polyp detection in average-risk patients**

Level of agreement: (i) accept completely 42%; (ii) accept with some reservation 39%; (iii) accept with major reservation 19%; (iv) reject with reservation 0%; (v) reject completely 0%.
Clinical question: Does the use of IEE improve the detection of polyps in average-risk patients?

Image-enhanced endoscopy: Image-enhanced endoscopy is an endoscopic imaging method used to improve the visualization of small blood vessels and mucosal surface patterns on polyps during endoscopy. Generally, IEE consists of two main types: (i) dye-based IEE (chromoendoscopy); and (ii) equipment-based IEE. Equipment-based IEE is subgrouped into optical IEE [narrow-band imaging (NBI), blue laser imaging (BLI)] and electronic IEE [i-scan, Fuji Intelligent Color Enhancement (FICE), autofluorescence imaging (AFI)]31,32

Two meta-analyses in 2014 and 2016 found strong evidence that chromoendoscopy enhances the detection of polyps in the colon and rectum.33,34 Chromoendoscopy yielded a significantly higher detection rate of neoplastic polyp [odds ratio (OR) 1.53, 95% confidence interval (CI) 1.31–1.79; 7 trials; 2727 participants]. There were no adverse events related to the use of contrast dye in those studies.

Narrow-band imaging. Although recent meta-analyses have confirmed that NBI is equally as effective as high-definition white light (SD WL) colonoscopy,34–38 One meta-analysis confirmed a prolonged withdrawal time in the NBI group and an improved rate of detection for flat adenomas. Second-generation NBI (190 series), which provides brighter images than the previous model (180 series), has become available. Second-generation NBI increased the ADR significantly in comparison with HD WL colonoscopy (48% vs 34%; P = 0.01) in one RCT.39 Detection of polyps and sessile serrated polyps was also increased in another RCT, but the rate of detection of adenoma did not change.40 However, one study concluded that second-generation NBI did not improve polyp detection.41

Table 3 List of statements

| Statements                                                                 | Evidence | Recommendation | Agreement (%) |
|---------------------------------------------------------------------------|----------|----------------|---------------|
| 1 Adequate bowel preparation is essential for high-quality colonoscopy    | II-2     | B              | 96            |
| 2 Use of antispasmodic agents during colonoscopy is useful for lesion detection | I        | C              | 92            |
| 3-1 Image-enhanced endoscopy can improve polyp detection in average-risk patients | I        | B              | 81            |
| 3-2 Chromoendoscopy improves detection of dysplasia in patients with IBD  | III      | C              | 92            |
| 4 Adenoma detection rate is an important quality indicator and should be monitored | II-2     | A              | 100           |
| 5 Colonoscopy findings should be well documented                           | III      | C              | 100           |
| 6 Complication rates should be monitored as one of the quality indicators for colonoscopy | II       | B              | 92            |
| 7 Cecal intubation rate should be monitored as an important quality indicator | II-2     | A              | 100           |
| 8 Cap-assisted colonoscopy is recommended as an aid to improve polyp detection | I        | B              | 92            |
| 9 Macrscopic classification using indigocarmine spray is recommended for characterization of colorectal lesions | III      | C              | 92            |
| 10 Image-enhanced endoscopy and/or magnifying endoscopy can be used by trained endoscopists for accurate prediction of histology | II-2     | B              | 91            |

Level of evidence: I.
Level of recommendation: B.

© 2018 The Authors. Digestive Endoscopy published by John Wiley & Sons Australia, Ltd on behalf of Japan Gastroenterological Endoscopy Society.
**Statement 3-2: Chromoendoscopy improves detection of dysplasia in patients with irritable bowel disease (IBD)**

Level of agreement: (i) accept completely 54%; (ii) accept with some reservation 38%; (iii) accept with major reservation 8%; (iv) reject with reservation 0%; (v) reject completely 0%.

Level of evidence: III.

Level of recommendation: C.

Clinical question: Can IEE improve the detection of dysplasia in patients with IBD?

Two meta-analyses in 2011 and 2013 confirmed the superiority of capsule endoscopy (CE) with targeted biopsy over SD WL colonoscopy with random biopsy (6% increase in the yield for dysplasia).46,47 As a result, many international guidelines now recommend the routine use of pancolonic chromoendoscopy with targeted biopsy for neoplasia surveillance in patients with IBD.48–52

**Narrow-band imaging.** Studies comparing NBI with standard WL colonoscopy have not shown any improvement in the detection of dysplasia.53–55 When compared to chromoendoscopy, NBI seemed to have lower dysplasia detection but the differences were not statistically significant.56–58 However, in one recent RCT, the new version of NBI was not inferior to pancolonic chromoendoscopy and had a shorter procedure duration.59

**i-Scan and FICE.** There are no published data available for FICE, i-scan and BLI in the context of colitis surveillance. Therefore, current evidence does not support the use of equipment-based IEE for surveillance of dysplasia in IBD.

**Statement 4: Adenoma detection rate is an important quality indicator and should be monitored**

Level of agreement: (i) accept completely 83%; (ii) accept with some reservation 17%; (iii) accept with major reservation 0%; (iv) reject with reservation 0%; (v) reject completely 0%.

Level of evidence: II-2.

Level of recommendation: A.

Clinical question: Can the ADR be used as a quality indicator of colonoscopy?

Several cohort studies have shown a close association between ADR and subsequent risk of post-colonoscopy CRC (PCCRC) or colonoscopy interval cancers (Table 4).5,60–63 Results from a Polish screening program were first to demonstrate that the ADR is inversely correlated with the risk of interval CRC.60 Baxter et al.61 showed that a low ADR increases the likelihood of proximal PCCRC. Corley et al.5 reported that the ADR was inversely associated with not only the incidence of CRC, but also the risk of more advanced CRC and CRC mortality, each 1% increase in ADR decreasing CRC mortality by 5%. The only report available for the FIT-based screening program in Taiwan showed that ADR, together with the cecal intubation rate and baseline colonoscopy findings, was associated with colonoscopy interval cancers.62 The benchmark threshold for ADR varies among different programs as it may be affected by the prevalence of adenoma in the population, type of primary screening test used (FIT or colonoscopy), and biological factors such as gender and age. Traditionally, the proportion of subjects with at least one neoplastic lesion among all subjects that underwent colonoscopy was the standard way to define ADR. However, there is a concern that endoscopists may focus on finding one adenoma only and, once they have done so, their attention may wane knowing that they have already contributed to the ADR. This situation may lead to an increase in missed neoplasia (the so-called “one and done” phenomenon). Modified ADR metrics, such as APP (adenoma per positive participant), ADR-plus, polypectomy rate, proximal ADR, AADR (advanced adenoma detection rate), or SSADR (sessile serrated adenoma/polyp detection rate), are now being explored.64–69 It is also important to know that the ADR in a FIT-based screening program is expected to be higher than that for colonoscopy-based screening.70

**Statement 5: Colonoscopy findings should be well documented**

Level of agreement: (i) accept completely 95%; (ii) accept with some reservation 5%; (iii) accept with major reservation 0%; (iv) reject with reservation 0%; (v) reject completely 0%.

Level of evidence: III.

Level of recommendation: C.

Clinical question: How should findings of colonoscopy be documented?
For each lesion detected by colonoscopy, location, size, morphology, optical diagnosis and intervention should be documented, and images captured. Documentation of procedural findings is central to the practice of quality colonoscopy. The report is an essential communication tool, serving as a permanent clinical and legal record of the procedure, and facilitating exchange of information between health-care providers.\(^{71}\) Quality of colonoscopy is under scrutiny,\(^ {10,12,72}\) and performance indicators are known to predict the incidence of post-colonoscopy (interval) CRC.\(^ {5,10}\) Multiple studies have shown deficits and variations in the quality of reporting. Reports are often incomplete, with lack of documentation of key procedural elements such as bowel preparation quality, polypl size and morphology.\(^ {73–75}\) As in other aspects of colonoscopy practice, the quality of colonoscopy reporting varies significantly between endoscopists, endoscopy units, and geographical regions.\(^ {76–78}\) Electronic reporting systems are known to be associated with more complete reporting.\(^ {79,80}\)

The European Society of Gastrointestinal Endoscopy (ESGE) position statement on reporting systems in endoscopy has emphasized the need for structured terminology with limitations to the use of free-text data entry.\(^ {81}\) This requires a standardized language for GI endoscopy and the use of “minimal standard terminology” for recommended reporting terms and structure.\(^ {82,83}\) In the USA, the Quality Assurance Task Group of the National Colorectal Cancer Round Table (NCCRT) has developed a standardized colonoscopy reporting and data system (C-O-RADS) to improve the quality of colonoscopy.\(^ {79}\) The recommendations for colonoscopic findings include standardized descriptors for colonic polyps, emphasizing that communication of findings is an important determinant of risk status and subsequent surveillance. For each polyp, CO-RADS-recommended descriptors are anatomical location, size, morphology, method of removal, completeness of removal, retrieval and submission for pathological evaluation. Documentation of lesion location, size, morphology, optical diagnosis and intervention for each lesion at colonoscopy allows determination of the risk for

### Table 4

| Author          | Study population                                                                 | Association of ADR and interval CRC risk |
|-----------------|----------------------------------------------------------------------------------|------------------------------------------|
| Corley et al.\(^5\) | Kaiser Permanente Northern California, 314 872 colonoscopies by 136 endoscopists, 1998–2010 | ADR: 0.0735–0.1905: reference 0.1906–0.2385: HR = 0.93 (0.70–1.23) 0.2386–0.2840: HR = 0.85 (0.68–1.06) 0.2841–0.3350: HR = 0.70 (0.54–0.91) 0.3351–0.5251: HR = 0.52 (0.39–0.69) |
| Kaminski et al.\(^60\) | Polish national CRC screening program, 45 026 subjects by 186 endoscopists | ADR: ≥0.20: reference 0.15–0.199: HR = 10.94 (1.37–87.01) 0.11–0.149: HR = 10.75 (1.36–85.06) <0.11: HR = 12.50 (1.51–103.43) |
| Baxter et al.\(^61\) | Ontario Cancer Registry 34 312 individuals diagnosed with CRC, 2000–2005 | ADR: proximal CRC/distal CRC <0.1: reference 0.1–0.14:1.11 (0.81–1.53)/0.99 (0.73–1.35) 0.15–0.19: 0.75 (0.54–1.04)/0.78 (0.57–1.06) 0.20–0.24: 0.75 (0.52–1.07)/0.82 (0.58–1.16) 0.25–0.29 0.52 (0.35–0.79)/0.87 (0.61–1.24) >30: 0.61 (0.42–0.89)/0.79 (0.54–1.14) |
| Chiu et al.\(^62\) | Taiwanese Nationwide CRC screening program, 29 969 subjects underwent complete colonoscopy after positive FIT during 2004–2009 | ADR: hospital level >0.3: reference 0.30–0.15: HR = 1.57 (0.94–2.61) <0.15: HR = 3.09 (1.55–6.18) Polypectomy rate: 0–0.24: reference 0.24–0.33: OR = 0.84 (0.76–0.93) 0.33–0.43: OR = 0.80 (0.72–0.89) >0.43: OR = 0.70 (0.63–0.78) |
| Cooper et al.\(^63\) | Surveillance, Epidemiology, and End Results (SEER) Medicare database 57 839 patients aged 69 years underwent colonoscopy during 1994–2005 | ADR: proximal CRC/distal CRC <0.1: reference 0.1–0.14:1.11 (0.81–1.53)/0.99 (0.73–1.35) 0.15–0.19: 0.75 (0.54–1.04)/0.78 (0.57–1.06) 0.20–0.24: 0.75 (0.52–1.07)/0.82 (0.58–1.16) 0.25–0.29 0.52 (0.35–0.79)/0.87 (0.61–1.24) >30: 0.61 (0.42–0.89)/0.79 (0.54–1.14) |

ADR, adenoma detection rate; CRC, colorectal cancer; FIT, fecal immunochemical test.
metachronous neoplasia and the need for subsequent clinical follow up and colonoscopic surveillance.\textsuperscript{84,85} These findings also facilitate reporting of continuous quality improvement targets such as the ADR.\textsuperscript{14} Without adequate documentation, continuous quality improvement processes are not possible and opportunities for improvement cannot be identified.

**Statement 6: Complication rates should be monitored as one of the quality indicators for colonoscopy**

Level of agreement: (i) accept completely 50%; (ii) accept with some reservation 42%; (iii) accept with major reservation 8%; (iv) reject with reservation 0%; (v) reject completely 0%.
Level of evidence: II.
Level of recommendation: B.
Clinical question: Should complication rates be monitored as an indicator of colonoscopy quality?

As the indications for endoscopy increase, particularly in relation to therapeutic procedures, clinicians will have to deal with an increasing number of complications. Early diagnosis and interventions are important for management of complications related to endoscopy, and treatment sometimes requires a multidisciplinary approach.\textsuperscript{86} Complications vary from simple abdominal pain to more serious complications such as bleeding and perforation.\textsuperscript{87–89} There are legal implications to these events, which may be unfavorable for physicians even if there is no clear correlation between the medical action and a worsening health condition.\textsuperscript{90} Establishing a good doctor–patient relationship before any endoscopic procedure with realistic expectations can alleviate some of these stresses and help to provide improved clinical care when adverse events occur.\textsuperscript{91,92} Monitoring of complications has already become a standard quality indicator in many countries, and bleeding rate (<1%) and perforation rate (<0.1%) are often defined as the minimum threshold for assuring quality of endoscopic procedures.\textsuperscript{93}

**Statement 7: Cecal intubation rate should be monitored as an important quality indicator**

Level of agreement: (i) accept completely 89%; (ii) accept with some reservation 11%; (iii) accept with major reservation 0%; (iv) reject with reservation 0%; (v) reject completely 0%.
Level of evidence: II-2.
Level of recommendation: A.
Clinical question: Does a high cecal intubation rate improve the detection rate of adenomas and serrated lesions and decrease the incidence of interval cancers?

In terms of definition, cecal intubation is achieved when the tip of the colonoscope is passed beyond the ileocecal valve into the cecum.\textsuperscript{94} As interval or missed cancers and missed precancerous lesions are likely to occur in the right colon, ensuring intubation into the cecum is important.\textsuperscript{95–100} In 2002, the cecal intubation rate was recommended by the US Multi-Society Task Force (MSTF) on CRC as an indicator of colonoscopy quality. Cases with colon obstructed by CRC were generally included in the calculation of cecal intubation rates.\textsuperscript{94} In recent years, studies have been conducted to survey the impact of the cecal intubation rate on colorectal neoplasia detection. In the Canadian CRC screening cohort and the English Bowel Cancer Screening Programme, the cecal intubation rate was positively associated with the detection rate of adenomas and serrated lesions.\textsuperscript{26,101} A population-based analysis of CRC patients has shown that they were more likely to undergo incomplete colonoscopy.\textsuperscript{99} A study comparing the risk of interval CRC among endoscopists who used different cecal incubation rates found that interval cancers were less common among those with higher rates (>90%) relative to the others (<80%).\textsuperscript{61} Jover \textit{et al.}\textsuperscript{102} showed that a higher cecal intubation rate was associated with detection of proximal adenomas, and also with a higher ADR. Therefore, the cecal intubation rate should be monitored as an important quality indicator. To ensure the quality of colonoscopy, the MSTF has recommended that the cecal intubation rate should be more than 90% in all cases, and 95% in screening cases. Documentation of cecal intubation must be included in all endoscopic reports with photography of visualized landmarks when available.\textsuperscript{103}

**Statement 8: Cap-assisted colonoscopy is recommended as an aid to improve polyp detection**

Level of agreement: (i) accept completely 42%; (ii) accept with some reservation 50%; (iii) accept with major reservation 8%; (iv) reject with reservation 0%; (v) reject completely 0%.
Level of evidence: I.
Level of recommendation: B.
Clinical question: Does CAC improve polyp detection?
Cap-assisted colonoscopy is universally available in Asian countries and can marginally improve polyp or adenoma detection. However, it may only be beneficial for selected targets, such as trainees and endoscopists with a longer withdrawal time. Removal of all neoplastic lesions by colonoscopy can reduce the incidence of CRC and associated mortality and, hence, high-quality examination is crucial for effective CRC prevention. The ADR is an important quality indicator associated with the incidence of interval cancer or post-colonoscopy CRC. Considering the medical and economic situation in Asia, CAC is the only affordable device available for improving the ADR. Although the results from several studies have been conflicting,104–109 many have reported that CAC improved the ADR.110–118 Furthermore, three meta-analyses have demonstrated a marginal benefit for polyp or adenoma detection,119–121 and one other study has also reported the usefulness of CAC for detection of serrated polyps.122 Although some authors have suggested that CAC may be beneficial for selected endoscopists only (e.g. trainees with a longer withdrawal time, and with a low ADR),109,118 further studies to clarify this problem are desirable. Although CAC may shorten the cecal intubation time104,105,107 and reduce the level of patient discomfort,104,105,107 it may make rectal retroflexion difficult.

Statement 9: Macroscopic classification using indigocarmine spray is recommended for characterization of colorectal lesions

Level of agreement: (i) accept completely 63%; (ii) accept with some reservation 29%; (iii) accept with major reservation 8%; (iv) reject with reservation 0%; (v) reject completely 0%.

Level of evidence: III.

Level of recommendation: C.

Clinical question: Can chromoendoscopy improve the characterization of colorectal lesions?

The Paris classification is a globally used macroscopic classification that divides superficial neoplastic lesions into polypoid (Ip, Is) and non-polypoid (Ia, Ib, IIC, III).123 Recognition of gross appearance and macroscopic classification assists the diagnosis of neoplastic or non-neoplastic lesions and prediction of submucosal invasion.

The incidence of submucosal invasion is markedly higher for the non-polypoid type relative to the polypoid type (42.4% vs 21.0%) in the National Colorectal Cancer Screening in Japan.124 The alternative morphological term “laterally spreading tumor” (LST), proposed by Kudo, is now widely accepted in both Asian and Western countries.125 Although this is not an official term, the two LST subtypes – granular type (LST-G) and non-granular type (LST-NG) – are significantly associated with frequency of submucosal invasion (LST-NG 14% vs LST-G 7%; P < 0.01).126–128 However, the macroscopic type of some lesions is difficult to recognize (Fig. 4). For such cases, contrast chromoendoscopy using, for example, indigo-carmine dye spraying provides additional information that can improve macroscopic characterization. Furthermore, staining chromoendoscopy using crystal violet or methylene blue with magnifying endoscopy is useful for detailed observation of the pit pattern (surface pattern).

Statement 10: IEE and/or magnifying endoscopy can be used by trained endoscopists for accurate prediction of histology

Level of agreement: (i) accept completely 70%; (ii) accept with some reservation 21%; (iii) accept with major reservation 9%; (iv) reject with reservation 0%; (v) reject completely 0%.

Level of evidence: II-2.

Level of recommendation: B.

Clinical question: Can trained endoscopists predict histology accurately using IEE and/or magnifying endoscopy?

Image-enhanced endoscopy is a method for enhancing the visualization of small blood vessels and minute patterns on the mucosal surface and can include NBI, FICE/BLI, i-scan, confocal laser endomicroscopy (CLE), AFI, or chromoendoscopy.32 A number of articles have assessed the diagnostic performance of IEE with or without magnification for differentiating non-neoplastic from neoplastic polyps, and the overall diagnostic accuracy achieved is mostly more than 90%.129–141 Meta-analyses of NBI, i-scan, FICE, AFI, or CLE have shown that all techniques except for AFI achieved satisfactory diagnostic performance.142–147 However, the performance levels for histological prediction by non-experts are not as good as those by experts (e.g. routine use of NBI for more than 5 years).148,149 Some studies have shown that training modules or continuous feedback in vivo are beneficial for non-experts in improving their diagnostic performance.149–151 For diagnosis of CRC invasion depth, magnifying chromoendoscopy yielded the highest accuracy at 98.8%.152 It has also been reported that NBI and FICE/BLI could be useful for determining therapeutic strategies including endoscopic resection or surgery.153–161
Figure 4 Case of sessile serrated polyp (SSP) with cytological dysplasia in the sigmoid colon shows the importance of chromoendoscopy. (Left) Only two elevated, polypoid areas are clearly observable with conventional white light imaging. (Right) Macroscopic characterization (IIa) is markedly clear after indigocarmine spraying.

Figure 5 Estimated number of colorectal cancer (CRC) patients and CRC-related deaths in 2018.
DISCUSSION

C OLORECTAL CANCER IS one of the leading malignant diseases in Asia. In comparison with other continents, total number of CRC patients in the Asian population is markedly high according to the International Agency for Research on Cancer (IARC). In 2018, the Global Cancer Observatory (GLOBOCAN) estimation project showed that the total number of CRC patients and CRC-related deaths in Asia was estimated to be approximately 1 million and 500,000, respectively (Fig. 5). Although these gross numbers are affected by the explosive growth of the Asian population, it remains an important problem in Asia that the number of people suffering from CRC is the highest among all continents in the world. It has been clarified that CRC-related deaths can be prevented by identification and removal of early-stage neoplasia. Nevertheless, the detection rate and diagnostic accuracy for early-stage colorectal neoplasia vary among Asian countries. Quality of diagnostic colonoscopy must be improved or managed appropriately in each country to avoid missed cancers, yet no consensus for diagnostic colonoscopy of colorectal neoplasia has emerged in Asia.

Against this background, we have developed an Asian expert-based consensus on fundamental knowledge of colonoscopy to minimize differences in the quality of diagnostic colonoscopy throughout Asia. This is the first Asian consensus to be formulated for diagnostic colonoscopy based on scientific evidence and opinions from thorough discussions by Asian experts. This study achieved consensuses on several important points: adequate bowel preparation, use of antispasmodic agents, ADR using IEE or CAC, documentation methods, complication rates, cecal intubation rate, precise recognition of macroscopic classification, and histological prediction using IEE and/or magnifying endoscopy.

Although several consensus statements regarding screening, surveillance, and quality assurance have previously been published by different societies, consensuses on diagnostic endoscopy are limited. Our current Asian consensus differs in that we have focused on essential knowledge for achieving high performance in detection and diagnosis of colorectal neoplasia. To meet the urgent demand of standardized diagnostic strategy especially in Asia, our consensus was designed and developed to be simple and widely acceptable to many countries. In contrast to clinical guidelines, the consensus statement has an advantage in that it is free from cultural, economic, ethical, political, and technical concerns. For this reason, Asian countries may not accept or adopt entire Western guidelines for colonoscopy such as ESGE guidelines and American Society for Gastrointestinal Endoscopy guidelines. Furthermore, reviewing the literature alone cannot always provide sufficient evidence to answer certain clinical questions on diagnostic colonoscopy; therefore, expert opinions through the Delphi method can guide Asian endoscopists to standardize endoscopic diagnosis.

This consensus will provide a basis for further elaboration and modification to suit the needs of individual Asian countries in the context of current endoscopic diagnosis of early-stage colorectal neoplasia. We expect that this consensus will contribute to standardization of the quality of diagnostic colonoscopy in Asia and, hopefully, in other parts of the world. Future perspective of our group is to develop consensus statements on endoscopic treatment of GI neoplasia.

CONCLUSION

T HE ASIAN EXPERT members have held meetings to refine various points of consensus related to diagnostic endoscopy and have developed an expert-based consensus on standards of diagnostic colonoscopy for early-stage neoplasia.

ACKNOWLEDGMENTS

W E WOULD LIKE to thank Ang Tiing Leong, Daisuke Kikuchi, Enders Kwok Wai Ng, Hisashi Doyama, James Lau, Kenichi Goda, Kensi Yao, Lawrence Khek Yu Ho, Mitsuhiro Fujishiro, Noriya Uedo, Quach Trong Duc, Rupa Banerjee, Takui Gotoda, Than Aye, Vikneswaran Namaisvayam, and Yao Fang for valuable voting, discussing and debating.

CONFLICTS OF INTEREST

T HE CONSENSUS MEETING was supported by a non-government organization named Asian Novel Bio-Imaging and Intervention Group (ANBI2G) which focused on training and education of endoscopic diagnosis and management of early gastrointestinal cancers in Asia. The ANBI2G was supported by donations from Olympus Corporation and Takeda Pharmaceutical Company Limited. The authors have no conflicts of interest to declare in relation to this article.

REFERENCES

1 Sano Y, Byeon JS, Li XB, et al. Colorectal cancer screening of the general population in East Asia. Dig. Endosc. 2016; 28: 243–9.
2 Chiu HM, Hsu WF, Chang LC, Wu MH. Colorectal cancer screening in Asia. Curr. Gastroenterol. Rep. 2017; 19: 47.
3 Sung JJ, Ng SC, Chan FK, et al. Asia Pacific Working Group. An updated Asia Pacific Consensus Recommendations on colorectal cancer screening. Gut. 2015; 64: 121–32.
4 Zauber AG, Winawer SJ, O’Brien MJ, et al. Colonscopic polypectomy and long-term prevention of colorectal-cancer deaths. N. Engl. J. Med. 2012; 366: 687–96.
5 Corley DA, Jensen CD, Marks AR, et al. Adenoma detection rate and risk of colorectal cancer and death. N. Engl. J. Med. 2014; 370: 1298–306.
6 Løberg M, Kalager M, Holme Ø, et al. Long-term colorectal-cancer mortality after adenoma removal. N. Engl. J. Med. 2014; 371: 799–807.
7 Matsuda T, Saito Y, Fujii T, et al. Size does not determine the grade of malignancy of early invasive colorectal cancer. World J. Gastroenterol. 2009; 15: 2708–13.
8 Tanaka S, Oka S, Kaneko I, et al. Endoscopic submucosal dissection for colorectal neoplasm: possibility of standardization. Gastrointest. Endosc. 2007; 66: 100–7.
9 Ikematsu H, Yoda Y, Matsuda T, et al. Long-term outcomes after resection for submucosal invasive colorectal cancers. Gastroenterology 2013; 144: 551–9.
10 Kaminski MF, Wieszczcy P, Rupinski M, et al. Increased rate of adenoma detection associates with reduced risk of colorectal cancer and death. Gastroenterology 2017; 153: 98–105.
11 Rex DK, Schoenfeld PS, Cohen J, et al. Quality indicators for colonoscopy. Am. J. Gastroenterol. 2015; 110: 72–90.
12 Rex DK, Schoenfeld PS, Cohen J, et al. Quality indicators for colonoscopy. Gastrointest. Endosc. 2015; 81: 31–53.
13 Kaminski MF, Thomas-Gibson S, Bugajski M, et al. Performance measures for lower gastrointestinal endoscopy: a European Society of Gastrointestinal Endoscopy (ESGE) quality improvement initiative. United European Gastroenterol J. 2017; 5: 309–34.
14 Harewood GC, Sharma VK, de Garmo P. Impact of colonoscopy preparation quality on detection of suspected colonic neoplasia. Gastrointest. Endosc. 2003; 58: 76–9.
15 Froomlich F, Wietlisbach V, Goumans JJ, Burnand B, Vader JP. Impact of colonic cleansing on quality and diagnostic yield of colonoscopy: the European Panel of Appropriateness of Gastrointestinal Endoscopy European multicenter study. Gastrointest. Endosc. 2005; 61: 378–84.
16 Clark BT, Rustagi T, Laine L. What level of bowel prep quality requires early repeat colonoscopy: systematic review and meta-analysis of the impact of preparation quality on adenoma detection rate. Am. J. Gastroenterol. 2014; 109: 1714–23.
17 Clark BT, Protiva P, Nagar A, et al. Quantification of adequate bowel preparation for screening or surveillance colonoscopy in men. Gastroenterology 2016; 150: 396–405.
18 Hong SN, Sung IK, Kim JH, et al. The effect of the bowel preparation status on the risk of missing polyp and Adenoma during screening colonoscopy: a tandem colonoscopic study. Clin Endosc. 2012; 45: 404–11.
19 Saunders BP, Williams CB. Premedication with intravenous antispasmodic speeds colonoscope insertion. Gastrointest. Endosc. 1996; 43: 209–11.
20 Shaheen NJ, Robertson DJ, Crosby MA, et al. Hyoscymine as a pharmacological adjunct in colonoscopy: a randomized, double blinded, placebo-controlled trial. Am. J. Gastroenterol. 1999; 94: 2905–8.
21 Marshall JB, Patel M, Mahajan RJ, Early DS, King PD, Banerjee B. Benefit of intravenous antispasmodic (hyoscymine sulfate) as premedication for colonoscopy. Gastrointest. Endosc. 1999; 49: 720–6.
22 Yoo MW, Kim SY, Park SI, et al. Hyoscine for polyp detection during colonoscopy: a randomized double-blind controlled trial. Endoscopy 2004; 36: 720–2.
23 Mui LM, Ng EK, Chan KC, et al. Randomized, double-blinded, placebo-controlled trial of intravenously administered hyoscine N-butyl bromide in patients undergoing colonoscopy with patient-controlled sedation. Gastrointest. Endosc. 2004; 59: 22–7.
24 Ristikankare M, Karinen-Mantila H. The role of routinely given hyoscine-N-butylbromide in colonoscopy: a double-blind, randomized, placebo-controlled, clinical trial. Scand. J. Gastroenterol. 2015; 51: 368–73.
25 Rondonotti E, Zolk O, Amato A, et al. The impact of hyoscine-N-butylbromide on adenoma detection during colonoscopy: meta-analysis of randomized, controlled studies. Gastrointest. Endosc. 2014; 80: 1103–12.
26 Cui P, Yao J, Han HZ, Zhao YJ, Yang J. Does hyoscine butylbromide really improve polyp detection during colonoscopy? A meta-analysis of randomized controlled trials. World J. Gastroenterol. 2014; 20: 7034–9.
27 Ashraf I, Ashraf S, Siddique S, Nguyen DL, Choudhary A, Bechtold ML. Hyoscine for polyp detection during colonoscopy: a meta-analysis and systematic review. World J. Gastroenterol. 2014; 6: 549–54.
28 Madhoun MF, Ali T, Tierney WM, Maple JT. Effect of hyoscine N-butylbromide on adenoma detection rate: meta-analysis of randomized clinical trials. Dig. Endosc. 2015; 27: 354–60.
29 Corte C, Dahlenburg L, Selby W, et al. Hyoscine butylbromide administered at the cecum increases polyp detection: a randomized double-blind placebo-controlled trial. Endoscopy 2012; 44: 917–22.
30 Lee TJ, Rees CJ, Blanks RG, et al. Colonicoscopy factors associated with adenoma detection in a national colorectal cancer screening program. Endoscopy 2014; 46: 203–11.
31 Kaltenbach T, Sano Y, Friedland S, Soetikno R; American Gastroenterological Association, American Gastroenterological Association (AGA) Institute technology assessment on image-enhanced endoscopy. Gastroenterology 2008; 134: 327–40.
32 Tajiri H, Niwa H. Proposal for a consensus terminology in endoscopy: how should different endoscopic imaging techniques be grouped and defined? Endoscopy 2008; 40: 775–8.
33 Brown SR, Baraza W, Din S, Riley S. Chromoscopy versus conventional endoscopy for the detection of polyps in the colon and rectum. Cochrane Database Syst. Rev. 2016; 4: CD006439.
34 Omata F, Ohde S, Deshpande GA, Kobayashi D, Matsuda K, Fukui T. Image-enhanced, chromo, and cap-assisted...
colonoscopy for improving adenoma/neoplasia detection rate: a systematic review and meta-analysis. Scand. J. Gastroenterol. 2014; 49: 222–37.

35 Jin XF, Chai TH, Shi JW, Yang XC, Sun QY. Meta-analysis for evaluating the accuracy of endoscopy with narrow band imaging in detecting colorectal adenomas. J. Gastroenterol. Hepatol. 2012; 27: 882–7.

36 Nagomi A, Bjelakovic G, Petrovic B. Narrow band imaging versus conventional white light colonoscopy for the detection of colorectal polyps. Cochrane Database Syst. Rev. 2012; 1: CD008361.

37 Dinesen L, Chuaj TJ, Kaffes AJ. Meta-analysis of narrow-band imaging versus conventional colonoscopy for adenoma detection. Gastrointest. Endosc. 2012; 75: 604–11.

38 Pasha SF, Leighton JA, Das A, et al. Comparison of the yield and miss rate of narrow band imaging and white light endoscopy in patients undergoing screening or surveillance colonoscopy: a meta-analysis. Am. J. Gastroenterol. 2012; 107: 363–70.

39 Leung WK, Lo OS, Liu KS, et al. Detection of colorectal adenoma by narrow band imaging (HQ190) vs. high-definition white light colonoscopy: a randomized controlled trial. Am. J. Gastroenterol. 2014; 109: 855–63.

40 Horimatsu T, Sano Y, Tanaka S, et al. Next-generation narrow band imaging system for colonic polyp detection: a prospective multicenter randomized trial. Int. J. Colorectal Dis. 2015; 30: 947–54.

41 Rex DK, Clodfelter R, Rahmani F, et al. Narrow-band imaging versus white light for the detection of proximal colon serrated lesions: a randomized, controlled trial. Gastrointest. Endosc. 2016; 83: 166–71.

42 Chung SJ, Kim D, Song JH, et al. Comparison of detection and miss rates of narrow band imaging, flexible spectral imaging chromoendoscopy and white light at screening colonoscopy: a randomised controlled back-to-back study. Gut 2014; 63: 785–91.

43 Hoffman A, Loth L, Rey JW, et al. High definition plus colonoscopy combined with i-scan tone enhancement vs. high definition colonoscopy for colorectal neoplasia: a randomized trial. Dig. Liver Dis. 2014; 46: 991–6.

44 Hong SN, Choe WH, Lee JH, et al. Prospective, randomized, back-to-back trial evaluating the usefulness of i-SCAN in screening colonoscopy. Gastrointest. Endosc. 2012; 75: 1011–21.

45 Bowman EA, Pfau PR, Mitra A, et al. High definition colonoscopy combined with i-SCAN imaging technology is superior in the detection of adenomas and advanced lesions compared to high definition colonoscopy alone. Diagn Ther Endosc 2015; 2015: 167406.

46 Soetikno R, Subramanian V, Kaltenbach T, et al. The detection of nonpolypoid (flat and depressed) colorectal neoplasms in patients with inflammatory bowel disease. Gastroenterology 2013; 144: 1349–52.

47 Subramanian V, Mannath J, Ragu Nath K, Hawkey CJ. Meta-analysis: the diagnostic yield of chromoendoscopy for detecting dysplasia in patients with colonic inflammatory bowel disease. Aliment. Pharmacol. Ther. 2011; 33: 304–12.

48 Annese V, Daperno M, Rutter MD, et al. European evidence based consensus for endoscopy in inflammatory bowel disease. J. Crohns. Colitis 2013; 7: 982–1018.

49 Kaminski MF, Hassan C, Bisschops R, et al. Advanced imaging for detection and differentiation of colorectal neoplasia: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy 2014; 46: 435–49.

50 Kornbluth A, Sachar DB; Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. Am. J. Gastroenterol. 2010; 105: 501–23.

51 Laine L, Kaltenbach T, Barkun A, et al. SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease. Gastrointest. Endosc. 2015; 81: 489–501.

52 Mowat C, Cole A, Windsor A, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut 2011; 60: 571–607.

53 Dekker E, van den Broek FJ, Reitsma JB, et al. Narrow-band imaging compared with conventional colonoscopy for the detection of dysplasia in patients with longstanding ulcerative colitis. Endoscopy 2007; 39: 216–21.

54 Ignjatovic A, East JE, Subramanian V, et al. Narrow band imaging for detection of dysplasia in colitis: a randomized controlled trial. Am. J. Gastroenterol. 2012; 107: 885–90.

55 van den Broek FJ, Fockens P, van Eeden S, et al. Narrow-band imaging versus high-definition endoscopy for the diagnosis of neoplasia in ulcerative colitis. Endoscopy 2011; 43: 108–15.

56 Bisschops R, Bessisow T, Baert FJ, et al. Chromo-endoscopy versus narrow band imaging in ulcerative colitis: a prospective randomized controlled trial. Gastrointest. Endosc. 2012; 75: AB148.

57 Efthymiou M, Allen PB, Taylor AC, et al. Chromoendoscopy versus narrow band imaging for colonic surveillance in inflammatory bowel disease. Inflamm. Bowel Dis. 2013; 19: 2132–8.

58 Pellise M, Lopez-Ceron M, de Rodriguez Miguel C, et al. Narrow-band imaging as an alternative to chromoendoscopy for the detection of dysplasia in long-standing inflammatory bowel disease: a prospective, randomized, crossover study. Gastrointest. Endosc. 2011; 74: 840–8.

59 Watanabe K, Nishishita M, Shimamoto F, et al. Comparison between newly-developed narrow band imaging and panchromoendoscopy for surveillance colonoscopy in patients with longstanding ulcerative colitis: a prospective multicenter randomized controlled trial, navigator study. Gastrointest. Endosc. 2016; 83: AB172.

60 Kaminski MF, Regula J, Kraszewska E, et al. Quality indicators for colonoscopy and the risk of interval cancer. N. Engl. J. Med. 2010; 362: 1795–803.

61 Baxter NN, Sutrathar R, Forbes SS, Paszat LF, Saskin R, Rabeneck L. Analysis of administrative data finds endoscopist
quality measures associated with postcolonoscopy colorectal cancer. *Gastroenterology* 2011; 140: 65–72.
62. Chiu SY, Chuang SL, Chen SL, et al. Faecal haemoglobin concentration influences risk prediction of interval cancers resulting from inadequate colonoscopy quality: analysis of the Taiwanese Nationwide Colorectal Cancer Screening Program. *Gut* 2017; 66: 293–300.
63. Cooper GS, Xu F, Bamholtz Sloan JS, Schluchter MD, Koroukian SM. Prevalence and predictors of interval colorectal cancers in medicare beneficiaries. *Cancer* 2012; 118: 3044–52.
64. Aniwai S, Orkoonawat P, Viriyatstadakul V, et al. The secondary quality indicator to improve prediction of adenoma miss rate apart from adenoma detection rate. *Am. J. Gastroenterol.* 2016; 111: 723–9.
65. Ross WA, Thirumurthi S, Lynch PM, et al. Detection rates of premalignant polyps during screening colonoscopy: time to revise quality standards? *Gastrointest. Endosc.* 2015; 81: 567–74.
66. Wang HS, Pisegna J, Modi R, et al. Adenoma detection rate is necessary but insufficient for distinguishing high versus low endoscopist performance. *Gastrointest. Endosc.* 2013; 77: 71–8.
67. Gohel TD, Burke CA, Lankala P, et al. Polypectomy rate: a surrogate for adenoma detection rate varies by colon segment, gender, and endoscopist. *Clin. Gastroenterol. Hepatol.* 2014; 12: 1137–42.
68. Park SK, Kim HY, Lee CK, et al. Comparison of adenoma detection rate and adenoma per colonoscopy as a quality indicator of colonoscopy. *Scand. J. Gastroenterol.* 2016; 51: 886–90.
69. Greenspan M, Rajan KB, Baig A, Beck T, Mobarhan S, Melson J. Advanced adenoma detection rate is independent of nonadvanced adenoma detection rate. *Am. J. Gastroenterol.* 2013; 108: 1286–92.
70. Hilsden RJ, Bridges R, Dube C, et al. Defining benchmarks for adenoma detection rate and adenomas per colonoscopy in patients undergoing colonoscopy due to a positive fecal immunochemical test. *Am. J. Gastroenterol.* 2016; 111: 1743–9.
71. Williams JE, Faigel DO. Colonoscopy reports and current state of performance measures. *Gastrointest. Endosc. Clin. N. Am.* 2010; 20: 685–97.
72. Hewett DG, Rex DK. Improving colonoscopy quality through health-care payment reform. *Am. J. Gastroenterol.* 2010; 105: 1925–33.
73. Robertson DJ, Lawrence LB, Shaheen NJ, et al. Quality of colonoscopy reporting: a process of care study. *Am. J. Gastroenterol.* 2002; 97: 2651–6.
74. de Jonge V, Sint Nicolaas J, Cahen DL, et al. Quality evaluation of colonoscopy reporting and colonoscopy performance in daily clinical practice. *Gastrointest. Endosc.* 2012; 75: 98–106.
75. Lieberman DA, Faigel DO, Logan JR, et al. Assessment of the quality of colonoscopy reports: results from a multicenter consortium. *Gastrointest. Endosc.* 2009; 69: 645–53.
76. Cotton PB, Connor P, McGee D, et al. Colonoscopy: practice variation among 69 hospital-based endoscopists. *Gastrointest. Endosc.* 2003; 57: 352–7.
77. Singh H, Kaita L, Taylor G, Nugent Z, Bernstein C. Practice and documentation of performance of colonoscopy in a central Canadian health region. *Can J Gastroenterol Hepatol* 2014; 28: 185–90.
78. Palmer LB, Abbott DH, Hamilton N, Provenzale D, Fisher DA. Quality of colonoscopy reporting in community practice. *Gastrointest. Endosc.* 2010; 72: 321–7.
79. Lieberman D, Nadel M, Smith RA, et al. Standardized colonoscopy reporting and data system: report of the Quality Assurance Task Group of the National Colorectal Cancer Roundtable. *Gastrointest. Endosc.* 2007; 65: 757–66.
80. van Doorn SC, van Vliet J, Fockens P, Dekker E. A novel colonoscopy reporting system enabling quality assurance. *Endoscopy* 2014; 46: 181–7.
81. Brethauer M, Aabakken L, Dekker E, et al. Requirements and standards facilitating quality improvement for reporting systems in gastrointestinal endoscopy: European Society of Gastrointestinal Endoscopy (ESGE) Position Statement. *Endoscopy* 2016; 48: 291–4.
82. Delvaux M, Crespi M, Armengol-Miro JR, et al. Minimal standard terminology for digestive endoscopy: results of prospective testing and validation in the GASTER project. *Endoscopy* 2000; 32: 345–55.
83. Aabakken L, Rembacken B, LeMoine O, et al. Minimal standard terminology for gastrointestinal endoscopy - MST 3.0. *Endoscopy* 2009; 41: 727–8.
84. Hassan C, Quintero E, Dumonceau JM, et al. Post-polypectomy colonoscopy surveillance: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. *Endoscopy* 2013; 45: 842–51.
85. Lieberman DA, Rex DK, Winawer SJ, Giardiello FM, Johnson DA, Levin TR. Guidelines for colonoscopy surveillance after screening and polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer. *Gastroenterology* 2012; 143: 844–57.
86. Burgess NG, Bassan MS, McLeod D, Williams SJ, Byth K, Bourke MJ. Deep mural injury and perforation after screening and polypectomy colonoscopy surveillance: a consensus update by the US Multi-Society Task Force on Colorectal Cancer. *Gastroenterology* 2012; 143: 844–57.
87. Blero D, Deviere J. Endoscopic complications—avoidance and management. *Nat. Rev. Gastroenterol. Hepatol.* 2012; 9: 162–72.
88. Marquez Azalgara V, Sewitch M, Joseph L, Barkun AN. Rates of minor adverse events and health resource utilization postcolonoscopy. *Can J Gastroenterol Hepatol* 2014; 28: 595–9.
89. Fujiya M, Tanaka K, Dokoshi T, et al. Efficacy and adverse events of EMR and endoscopic submucosal dissection for the treatment of colon neoplasms: a meta-analysis of studies comparing EMR and endoscopic submucosal dissection. *Gastrointest. Endosc.* 2015; 81: 583–95.
90. Zandonà C, Turrina S, Pasin N, De Leo D. Medico-legal considerations in a case of splenic injury that occurred during colonoscopy. *J. Forensic Leg. Med.* 2012; 19: 229–33.

© 2018 The Authors. *Digestive Endoscopy* published by John Wiley & Sons Australia, Ltd on behalf of Japan Gastroenterological Endoscopy Society.
systematic review and meta-analysis. Dis. Colon Rectum 2012; 55: 218–25.

121 Morgan J, Thomas K, Lee-Robichaud H, Nelson RL, Braungart S. Transparent cap colonoscopy versus standard colonoscopy to improve caecal intubation. Cochrane Database Syst. Rev. 2012; 12: CD008211.

122 Rzoã¼f G, Gupta N, Wani S, Sharma P, Bansal A, Rastogi A. Cap assisted colonoscopy for the detection of serrated polyps: a post-hoc analysis. BMC Gastroenterol. 2015; 15: 11.

123 The Paris endoscopic of superficial neoplastic lesions: esophageal, stomach, and colon. Gastrointest Endosc 2003; 58 (Suppl).

124 Kudo S, Lambert R, Allen JI, et al. Nonpolyoid neoplastic lesions of the colorectal mucosa. Gastrointest Endosc 2008; 68 (Suppl).

125 Kudo S. About laterally spreading tumor. Early Colorectal Cancer 1998; 2: 477–81.

126 Uraoka T, Saito Y, Matsuda T, et al. Endoscopic indications for endoscopic mucosal resection of laterally spreading tumours in the colorectum. Gut 2006; 55: 1592–7.

127 Oka S, Tanaka S, Kanao H, Oba S, Chayama K. Therapeutic strategy for colorectal laterally spreading tumor. Dig. Endosc. 2009; 21(Suppl 1): S43–6.

128 Shigita K, Oka S, Tanaka S, et al. Clinical significance and validity of the subclassification for colorectal laterally spreading tumor granular type. J. Gastroenterol. Hepatol. 2016; 31: 973–9.

129 Kato S, Fujii T, Koba I, et al. Assessment of colorectal lesions using magnifying colonoscopy and mucosal dye spraying: can significant lesions be distinguished? Endoscopy 2001; 33: 306–10.

130 Hurlstone DP, Cross SS, Adam I, et al. Efficacy of high magnification chromoscopic colonoscopy for the diagnosis of neoplasia in flat and depressed lesions of the colorectum: a prospective analysis. Gut 2004; 53: 284–90.

131 Fu KI, Sano Y, Kato S, et al. Chromoendoscopy using indigo carmine dye spraying with magnifying observation is the most reliable method for differential diagnosis between non-neoplastic and neoplastic colorectal lesions: a prospective study. Endoscopy 2004; 36: 1089–93.

132 Machida H, Sano Y, Hamamoto Y, et al. Narrow-band imaging in the diagnosis of colorectal mucosal lesions: a pilot study. Endoscopy 2004; 36: 1094–8.

133 Sano Y, Ikematsu H, Fu KI, et al. Meshed capillary vessels by use of narrow-band imaging for differential diagnosis of small colorectal polyps. Gastrointest. Endosc. 2009; 69: 278–83.

134 Rex DK. Narrow-band imaging without optical magnification for histologic analysis of colorectal polyps. Gastroenterology 2009; 136: 1174–81.

135 Ignjatovic A, East JE, Suzuki N, Vance M, Guenther T, Saunders BP. Optical diagnosis of small colorectal polyps at routine colonoscopy (Detect InSpect ChAracterise Resect and Discard; DISCARD trial): a prospective cohort study. Lancet Oncol. 2009; 10: 1171–8.

136 Zachary H, Henry, Paul Yeaton, Vanessa M, et al. Meshed capillary vessels found on narrow-band imaging without optical magnification effectively identifies colorectal neoplasia: a North American validation of the Japanese experience. Gastrointest. Endosc.. 2010; 72: 118–26.

137 Hewett DG, Kaltenbach T, Sano Y, et al. Validation of a simple classification system for endoscopic diagnosis of small colorectal polyps using narrow-band imaging. Gastroenterology 2012; 143: 599–607.

138 Kaltenbach T, Rastogi A, Rouse RV, et al. Real-time optical diagnosis for diminutive colorectal polyps using narrow-band imaging: the VALID randomized clinical trial. Gut 2015; 64: 1569–77.

139 Yoshida N, Yagi N, Inada Y, et al. Ability of a novel blue laser imaging system for the diagnosis of colorectal polyps. Dig. Endosc. 2014; 26: 250–8.

140 dos Santos CE, Lima JC, Lopes CV, et al. Computerized virtual chromoendoscopy versus indigo carmine chromoendoscopy combined with magnification for diagnosis of small colorectal lesions: a randomized and prospective study. Eur. J. Gastroenterol. Hepatol. 2010; 22: 1364–71.

141 Basford PJ, Longcroft-Wheaton G, Higgins B, Bhandari P. High-definition endoscopy with i-Scan for evaluation of small colon polyps: the HiSCOPE study. Gastrointest. Endosc. 2014; 79: 111–8.

142 ASGE Technology Committee, Abu Dayyeh BK, Thosani N, Konda V, et al. ASGE Technology Committee systematic review and meta-analysis assessing the ASGE PIVI thresholds for adopting real-time endoscopic assessment of the histology of diminutive colorectal polyps. Gastrointest. Endosc.. 2015; 81: 502.e1–16.

143 McGill SK, Evangelou E, Ioannidis JP, Soetikno RM, Kaltenbach T. Narrow band imaging to differentiate neoplastic and non-neoplastic colorectal polyps in real time: a meta-analysis of diagnostic operating characteristics. Gut 2013; 62: 1704–13.

144 Wanders LK, East JE, Uitentuis SE, Leeflang MM, Dekker E. Diagnostic performance of narrowed spectrum endoscopy, autofluorescence imaging, and confocal laser endomicroscopy for optical diagnosis of colonic polyps: a meta-analysis. Lancet Oncol. 2013; 14: 1337–47.

145 Wu L, Li Y, Li Z, Cao Y, Gao F. Diagnostic accuracy of narrow-band imaging for the differentiation of neoplastic from non-neoplastic colorectal polyps: a meta-analysis. Colorectal Dis. 2013; 15: 3–11.

146 Rex DK, Kahi C, O’Brien M, et al. The American Society for Gastrointestinal Endoscopy PIVI (Preservation and Incorporation of Valuable Endoscopic Innovations) on real-time endoscopic assessment of the histology of diminutive colorectal polyps. Gastrointest. Endosc. 2011; 73: 419–22.

147 van den Broek FJ, Reitsma JB, Curvers WL, Fockens P, Dekker E. Systematic review of narrow-band imaging for the detection and differentiation of neoplastic and nonneoplastic lesions in the colon (with videos). Gastrointest. Endosc. 2009; 69: 124–35.

148 Ladabaum U, Fioritto A, Mitani A, et al. Real-time optical biopsy of colon polyps with narrow band imaging in
community practice does not yet meet key thresholds for clinical decisions. Gastroenterology 2013: 144: 81–91.

149 Higashi R, Uraoka T, Kato J, et al. Diagnostic accuracy of narrow-band imaging and pit pattern analysis significantly improved for less-experienced endoscopists after an expanded training program. Gastrointest. Endosc. 2010; 72: 127–35.

150 McGill SK, Soetikno R, Rastogi A, et al. Endoscopists can sustain high performance for the optical diagnosis of colorectal polyps following standardized and continued training. Endoscopy 2015; 47: 200–6.

151 Dai J, Shen YF, Sano Y, et al. Evaluation of narrow-band imaging and pit pattern analysis significantly improved for less-experienced endoscopists after an expanded training program. Gastrointest. Endosc. 2010; 72: 127–35.

152 Matsuda T, Fujii T, Saito Y, et al. Efficacy of the invasive/non-invasive pattern by magnifying chromoendoscopy to estimate the depth of invasion of early colorectal neoplasms. Am. J. Gastroenterol. 2008; 103: 2700–6.

153 Backes Y, Moss A, Reitsma JB, Siersema PD, Moons LM. Narrow band imaging, magnifying chromoendoscopy, and gross morphological features for the optical diagnosis of T1 colorectal cancer and deep submucosal invasion: a systematic review and meta-analysis. Am. J. Gastroenterol. 2017 Jan; 112: 54–64.

154 Zhang JJ, Gu LY, Chen XY, Gao YJ, Ge ZZ, Li XB. Endoscopic diagnosis of invasion depth for early colorectal carcinomas: a prospective comparative study of narrow-band imaging, acetic acid, and crystal violet. Medicine (Baltimore). 2015; 94: 528.

155 Hayashi N, Tanaka S, Hewett DG, et al. Endoscopic prediction of deep submucosal invasive carcinoma: validation of the narrow-band imaging international colorectal endoscopic (NICE) classification. Gastrointest. Endosc. 2013; 78: 625–32.

156 Sakamoto T, Saito Y, Nakajima T, Matsuda T. Comparison of magnifying chromoendoscopy and narrow-band imaging in estimation of early colorectal cancer invasion depth: a pilot study. Dig. Endosc. 2011; 23: 118–23.

157 Ikematsu H, Matsuda T, Sano Y, et al. Efficacy of capillary pattern type IIIA/IIIB by magnifying narrow band imaging for estimating depth of invasion of early colorectal neoplasms. BMC Gastroenterol. 2010; 27(10): 33.

158 Kanao H, Tanaka S, Oka S, Hirata M, Yoshida S, Chayama K. Narrow band imaging magnification predicts the histology and invasion depth of colorectal tumors. Gastrointest. Endosc. 2009; 69: 631–6.

159 Wada Y, Kudo S, Kashida H, et al. Diagnosis of colorectal lesions with the magnifying narrow-band imaging system. Gastrointest. Endosc. 2009; 70: 522–31.

160 Nikami T, Saito S, Tajiri H, Masahiro I. The evaluation of histological atypia and depth of invasion of colorectal lesions using magnified endoscopy with narrow-band imaging. Gastroenterol Endosc 2009; 51: 10–9.

161 Yoshida N, Hisabe T, Inada Y, et al. The ability of a novel blue laser imaging system for the diagnosis of invasion depth of colorectal neoplasms. J. Gastroenterol. 2014; 49: 73–80.

162 Rembacken B, Hassan C, Riemann JF, et al. Quality in screening colonoscopy: position statement of the European Society of Gastrointestinal Endoscopy (ESGE). Endoscopy 2012; 44: 957–68.

163 Hassan C, Brethauer M, Kaminski MF, et al. Bowel preparation for colonoscopy: European Society of Gastrointestinal Endoscopy (ESGE) guideline. Endoscopy 2013; 45: 142–50.

164 Jover R, Dekker E, Schoen RE, et al. Colonoscopy quality requisites for selecting surveillance intervals: a World Endoscopy Organization Delphi Recommendation. Dig. Endosc. 2018; 30: 750–9.

165 Cairns SR, Scholefield JH, Steele RJ, et al. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut 2010; 59: 666–90.

166 Kahi CJ, Boland CR, Dominitz JA, et al. Colonoscopy surveillance after colorectal cancer resection: recommendations of the US multi-society task force on colorectal cancer. Gastrointest. Endosc. 2016; 83: 489–98.

167 Rex DK, Boland CR, Dominitz JA et al. Colorectal cancer screening: recommendations for physicians and patients from the U.S. Multi-Society Task Force on Colorectal Cancer. Gastrointest. Endosc. 2017; 86: 18–33.

168 Chiu PWY, Uedo N, Singh R et al. An Asian consensus on standards of diagnostic upper endoscopy for neoplasia. Gut. 2018; https://doi.org/10.1136/gutjnl-2018-317111.